{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:24:34Z","timestamp":1792801474964,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Region Pays de la Loire","award":["DesEpiD"],"award-info":[{"award-number":["DesEpiD"]}]},{"name":"Institut de Recherche en Sant\u00e9 Respiratoire des Pays de la Loire","id":[{"id":"https:\/\/ror.org\/00tka3k49","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"INSERM (France)\/ CNRST","award":["agreement 2015\/2016"],"award-info":[{"award-number":["agreement 2015\/2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13148-018-0517-9","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T07:30:07Z","timestamp":1529307007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma"],"prefix":"10.1186","volume":"10","author":[{"given":"Douae","family":"Bensaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Blondy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Dehame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Errami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-3747","authenticated-orcid":false,"given":"Christophe","family":"Blanquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"517_CR1","first-page":"260","volume":"17","author":"JC Wagner","year":"1960","unstructured":"Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260\u201371.","journal-title":"Br J Ind Med"},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, et al. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"517_CR3","doi-asserted-by":"crossref","unstructured":"Pan Y, Liu G, Zhou F, Su B, Li Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 2018;18:1\u201314.","DOI":"10.1007\/s10238-017-0467-0"},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-4939-1804-1_12","volume":"1238","author":"X Zhang","year":"2015","unstructured":"Zhang X, Tang N, Rishi AK, et al. Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options. Methods Mol Biol. 2015;1238:235\u201347.","journal-title":"Methods Mol Biol"},{"key":"517_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/ng1531","volume":"37","author":"MF Fraga","year":"2005","unstructured":"Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391\u2013400.","journal-title":"Nat Genet"},{"key":"517_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc2876","volume":"10","author":"P Chi","year":"2010","unstructured":"Chi P, Allis CD, Wang GG. Covalent histone modifications\u2014miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10:457\u201369.","journal-title":"Nat Rev Cancer"},{"key":"517_CR7","doi-asserted-by":"publisher","first-page":"14007","DOI":"10.1073\/pnas.96.24.14007","volume":"96","author":"AR Karpf","year":"1999","unstructured":"Karpf AR, Peterson PW, Rawlins JT, et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A. 1999;96:14007\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bjc.6600174","volume":"86","author":"L Sigalotti","year":"2002","unstructured":"Sigalotti L, Coral S, Altomonte M, et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer. 2002;86:979\u201382.","journal-title":"Br J Cancer"},{"key":"517_CR9","first-page":"1766","volume":"54","author":"J Weber","year":"1994","unstructured":"Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2032-deoxycytidine. Cancer Res. 1994;54:1766\u201371.","journal-title":"Cancer Res"},{"key":"517_CR10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","volume":"5","author":"H Li","year":"2014","unstructured":"Li H, Chiappinelli KB, Guzzetta AA, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:587\u201398.","journal-title":"Oncotarget"},{"key":"517_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162:961\u201373.","journal-title":"Cell"},{"key":"517_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1183\/09031936.00081310","volume":"38","author":"S Leclercq","year":"2011","unstructured":"Leclercq S, Gueugnon F, Boutin B, et al. A 5-aza-2\u2032-deoxycytidine\/valproate combination induces cytotoxic T-cell response against mesothelioma. Eur Respir J. 2011;38:1105\u201316.","journal-title":"Eur Respir J"},{"key":"517_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/00002371-200103000-00010","volume":"24","author":"TS Weiser","year":"2001","unstructured":"Weiser TS, Guo ZS, Ohnmacht GA, et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001;24:151\u201361.","journal-title":"J Immunother"},{"key":"517_CR14","first-page":"117","volume":"3","author":"N Martinet","year":"2011","unstructured":"Martinet N, Bertrand P. Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag Res. 2011;3:117\u201341.","journal-title":"Cancer Manag Res"},{"key":"517_CR15","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1021\/jm9002439","volume":"52","author":"C Charrier","year":"2009","unstructured":"Charrier C, Clarhaut J, Gesson JP, et al. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. J Med Chem. 2009;52:3112\u20135.","journal-title":"J Med Chem"},{"key":"517_CR16","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.18632\/oncotarget.2056","volume":"5","author":"F Gueugnon","year":"2014","unstructured":"Gueugnon F, Cartron PF, Charrier C, et al. New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells. Oncotarget. 2014;5:4504\u201315.","journal-title":"Oncotarget"},{"key":"517_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/cas.12695","volume":"106","author":"K Adachi","year":"2015","unstructured":"Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945\u201350.","journal-title":"Cancer Sci"},{"key":"517_CR18","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","volume":"178","author":"F Gueugnon","year":"2011","unstructured":"Gueugnon F, Leclercq S, Blanquart C, et al. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol. 2011;178:1033\u201342.","journal-title":"Am J Pathol"},{"key":"517_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0022-1759(01)00477-X","volume":"258","author":"JF Fonteneau","year":"2001","unstructured":"Fonteneau JF, Larsson M, Somersan S, et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods. 2001;258:111\u201326.","journal-title":"J Immunol Methods"},{"key":"517_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","volume":"97","author":"A Atmaca","year":"2007","unstructured":"Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer. 2007;97:177\u201382.","journal-title":"Br J Cancer"},{"key":"517_CR21","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","volume":"25","author":"P Munster","year":"2007","unstructured":"Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007;25:1979\u201385.","journal-title":"J Clin Oncol"},{"key":"517_CR22","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923\u201331.","journal-title":"J Clin Oncol"},{"key":"517_CR23","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.1158\/1078-0432.CCR-06-1802","volume":"12","author":"EH Rubin","year":"2006","unstructured":"Rubin EH, Agrawal NG, Friedman EJ, et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res. 2006;12:7039\u201345.","journal-title":"Clin Cancer Res"},{"key":"517_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","volume":"45","author":"A Salmaninejad","year":"2016","unstructured":"Salmaninejad A, Zamani MR, Pourvahedi M, et al. Cancer\/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Investig. 2016;45:619\u201340.","journal-title":"Immunol Investig"},{"key":"517_CR25","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023\u201339.","journal-title":"Onco Targets Ther"},{"key":"517_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/mol.65.1.18","volume":"65","author":"AR Karpf","year":"2004","unstructured":"Karpf AR, Lasek AW, Ririe TO, et al. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2\u2032-deoxycytidine. Mol Pharmacol. 2004;65:18\u201327.","journal-title":"Mol Pharmacol"},{"key":"517_CR27","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"AA Lane","year":"2009","unstructured":"Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459\u201368.","journal-title":"J Clin Oncol"},{"key":"517_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejphar.2009.10.011","volume":"625","author":"LS Kristensen","year":"2009","unstructured":"Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol. 2009;625:131\u201342.","journal-title":"Eur J Pharmacol"},{"key":"517_CR29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2174\/156800911797264761","volume":"11","author":"C Blanquart","year":"2011","unstructured":"Blanquart C, Francois M, Charrier C, et al. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds. Curr Cancer Drug Targets. 2011;11:919\u201328.","journal-title":"Curr Cancer Drug Targets"},{"key":"517_CR30","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-08-2999","volume":"15","author":"MG Fakih","year":"2009","unstructured":"Fakih MG, Pendyala L, Fetterly G, et al. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res. 2009;15:3189\u201395.","journal-title":"Clin Cancer Res"},{"key":"517_CR31","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1158\/1078-0432.CCR-12-3165","volume":"19","author":"I Gojo","year":"2013","unstructured":"Gojo I, Tan M, Fang HB, et al. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res. 2013;19:1838\u201351.","journal-title":"Clin Cancer Res"},{"key":"517_CR32","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.0050038","volume":"5","author":"S Floess","year":"2007","unstructured":"Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5:e38.","journal-title":"PLoS Biol"},{"key":"517_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4049\/jimmunol.1701128","volume":"200","author":"AR Victor","year":"2018","unstructured":"Victor AR, Weigel C, Scoville SD, et al. Epigenetic and posttranscriptional regulation of CD16 expression during human NK cell development. J Immunol. 2018;200:565\u201372.","journal-title":"J Immunol"},{"key":"517_CR34","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","volume":"20","author":"A Thomas","year":"2014","unstructured":"Thomas A, Rajan A, Szabo E, et al. A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res. 2014;20:5392\u2013402.","journal-title":"Clin Cancer Res"},{"key":"517_CR35","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/1078-0432.CCR-13-1576","volume":"20","author":"C Govindaraj","year":"2014","unstructured":"Govindaraj C, Tan P, Walker P, et al. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res. 2014;20:724\u201335.","journal-title":"Clin Cancer Res"},{"key":"517_CR36","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1652","volume":"13","author":"R Tao","year":"2007","unstructured":"Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13:1299\u2013307.","journal-title":"Nat Med"},{"key":"517_CR37","doi-asserted-by":"publisher","first-page":"948","DOI":"10.4161\/onci.20306","volume":"1","author":"L Shen","year":"2012","unstructured":"Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology. 2012;1:948\u201350.","journal-title":"Oncoimmunology"},{"key":"517_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ajh.23112","volume":"87","author":"MJ Kelly-Sell","year":"2012","unstructured":"Kelly-Sell MJ, Kim YH, Straus S, et al. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol. 2012;87:354\u201360.","journal-title":"Am J Hematol"},{"key":"517_CR39","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11095-013-1231-0","volume":"32","author":"S Zhu","year":"2015","unstructured":"Zhu S, Denman CJ, Cobanoglu ZS, et al. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res. 2015;32:779\u201392.","journal-title":"Pharm Res"},{"key":"517_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.febslet.2007.02.045","volume":"581","author":"H Ogbomo","year":"2007","unstructured":"Ogbomo H, Michaelis M, Kreuter J, et al. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett. 2007;581:1317\u201322.","journal-title":"FEBS Lett"},{"key":"517_CR41","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1073\/pnas.050588297","volume":"97","author":"S Kim","year":"2000","unstructured":"Kim S, Iizuka K, Aguila HL, et al. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A. 2000;97:2731\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaci.2013.07.020","volume":"132","author":"JS Orange","year":"2013","unstructured":"Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol. 2013;132:515\u201325. quiz 26","journal-title":"J Allergy Clin Immunol"},{"key":"517_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A Lopez-Soto","year":"2017","unstructured":"Lopez-Soto A, Gonzalez S, Smyth MJ, et al. Control of metastasis by NK cells. Cancer Cell. 2017;32:135\u201354.","journal-title":"Cancer Cell"},{"key":"517_CR44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molonc.2012.11.004","volume":"7","author":"PF Cartron","year":"2013","unstructured":"Cartron PF, Blanquart C, Hervouet E, et al. HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression. Mol Oncol. 2013;7:452\u201363.","journal-title":"Mol Oncol"},{"key":"517_CR45","first-page":"183","volume":"4","author":"H Nakashima","year":"2015","unstructured":"Nakashima H, Nguyen T, Chiocca EA. Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. Oncolytic Virother. 2015;4:183\u201391.","journal-title":"Oncolytic Virother"},{"key":"517_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-017-0358-y","volume":"9","author":"R Mazzone","year":"2017","unstructured":"Mazzone R, Zwergel C, Mai A, et al. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics. 2017;9:59.","journal-title":"Clin Epigenetics"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-018-0517-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T16:08:19Z","timestamp":1604419699000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-018-0517-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1186\/s13148-018-0517-9","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"29 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mesothelioma cell line use in this work belongs to a bio-collection of mesothelioma samples from patients (DC-2011-1399) recognized by the French ministry of research. All recruited patients had received no prior anticancer therapy and gave signed, informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"79"}}